Compound Detail
CHEMBL4297820
ROZANOLIXIZUMAB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4297820 |
| Name | ROZANOLIXIZUMAB |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
5
Known Names
5
Indications
1
Mechanisms
Drug Information
| Molecule Type | Antibody |
| First Approval | 2023 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| IgG receptor FcRn large subunit p51 inhibitor | INHIBITOR | IgG receptor FcRn large subunit p51 | ✓ | ✓ |
Indications
Myasthenia Gravis Purpura, Thrombocytopenic, Idiopathic Fibromyalgia Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Thrombocytopenia
ATC Classification
L04AG16
rozanolixizumab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSUPPRESSANTS
Data from ChEMBL 36 via Core Engine